News & Videos - VANDA PHARMACEUTICALS INC. - English

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review PR Newswire WASHINGTON, Jan. 8, 2025 WASHINGTON , Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As previously reported, Vanda has sought approval from the U.S. Food and Drug Administration (FDA) for tradipitant for the treatment of patients with gastroparesis. FDA declined to approve Vanda's New Drug Application...

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR Newswire WASHINGTON, Dec. 20, 2024 WASHINGTON , Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the treatment...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Vanda Pharmaceuticals stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at...

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences PR Newswire WASHINGTON, Nov. 12, 2024 WASHINGTON , Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced that the company will participate in the following upcoming investor conferences in November 2024 : The Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 . A corporate presentation is scheduled for 9:45 a.m. Eastern Time . The Jefferies 2024 London...

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire WASHINGTON, Nov. 6, 2024 Revenues for Q3 2024 were $47.7 million , an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges Fanapt ® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023 Fanapt ® long acting injectable program expected to be initiated in Q4 2024 Milsaperidone NDA for...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire NEW YORK, Nov. 2, 2024 NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or...

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 PR Newswire WASHINGTON, Oct. 30, 2024 Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024 , during which management will...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire NEW YORK, Oct. 25, 2024 NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire NEW YORK, Oct. 17, 2024 NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or...

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. PR Newswire WASHINGTON, Oct. 14, 2024 Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON , Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire NEW YORK, Oct. 9, 2024 NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA PR Newswire NEW YORK, Oct. 3, 2024 NEW YORK , Oct. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Vanda and certain of its officers and/or...

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis PR Newswire WASHINGTON, Sept. 19, 2024 WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024 , the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a...

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference PR Newswire WASHINGTON, Sept. 11, 2024 WASHINGTON , Sept. 11, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2024 Cantor Global Healthcare Conference in New York City on Thursday, September 19, 2024 . A fireside chat is scheduled for 8:00 a.m. Eastern Time . The fireside chat given at the 2024 Cantor Global Healthcare...

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference PR Newswire WASHINGTON, Sept. 4, 2024 WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment Conference in New York City on Tuesday, September 10, 2024 . A corporate presentation is scheduled for 2:00 p.m. Eastern Time . The corporate presentation given at the H.C....

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference PR Newswire WASHINGTON, Aug. 29, 2024 WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024 . A corporate presentation is scheduled for 11:00 a.m. Eastern Time . The corporate presentation given at the Wells Fargo 2024 Healthcare...

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results PR Newswire WASHINGTON, July 31, 2024 Revenues for Q2 2024 were $50.5 million , an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt ® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 PONVORY ® commercial launch in multiple sclerosis initiated in Q3 2024 Tradipitant NDA review for gastroparesis...

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire WASHINGTON, July 26, 2024 Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024 , during which management will discuss the...

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON, July 1, 2024 WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA , Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ ®...

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders PR Newswire WASHINGTON, June 19, 2024 WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal...